Literature DB >> 21691729

Detection methods of ZAP-70 in chronic lymphocytic leukemia.

Yin-Hua Wang1, Lei Fan, Wei Xu, Jian-Yong Li.   

Abstract

The clinical course of patients with chronic lymphocytic leukemia (CLL) is highly heterogeneous, with some patients experiencing rapid disease progression and others living for decades without requiring treatment. Immunoglobulin heavy chain variable region (IGHV) mutation status is a powerful prognostic factor in patients with CLL. The presence or absence of IGHV mutation status is currently the gold-standard prognostic factor, but this technique is labor-intensive and costly. The expression of ζ-chain-associated protein kinase 70 kDa (ZAP-70), detected by flow cytometry, has been served as a potential surrogate for the absence of IGHV mutation status since 2003. Given the current problems with the standardization of ZAP-70 assessment by flow cytometry, this chapter reviews the analysis of ZAP-70 expression by flow cytometry and the relative experimental conditions using the associated publications for "ZAP-70" and "detection method" on Medline since 2003. Thus, mean fluorescence intensity (MFI) ratio method yielded a more reproducible and easily adaptable method to routine use in the clinical diagnostic laboratory. In conclusion, though ZAP-70 is a valuable prognostic factor in CLL, detection methods of ZAP-70 remain to be fully standardized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691729     DOI: 10.1007/s10238-011-0148-3

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  56 in total

1.  MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal.

Authors:  M-E Marquez; P-A Deglesne; G Suarez; E Romano
Journal:  Int J Lab Hematol       Date:  2010-10-07       Impact factor: 2.877

2.  ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.

Authors:  Mark A Catherwood; Christine Matthews; Roberta Niblock; Edwina Dobbin; T C M Morris; H Denis Alexander
Journal:  Eur J Haematol       Date:  2006-04       Impact factor: 2.997

3.  Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.

Authors:  Nathalie Gachard; Aurélie Salviat; Catherine Boutet; Christine Arnoulet; Françoise Durrieu; Bernard Lenormand; Stéphane Leprêtre; Sylviane Olschwang; Fabrice Jardin; Marina Lafage-Pochitaloff; Dominique Penther; Danielle Sainty; Liliane Reminieras; Jean Feuillard; Marie C Béné
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

4.  Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis.

Authors:  T Taniguchi; T Kobayashi; J Kondo; K Takahashi; H Nakamura; J Suzuki; K Nagai; T Yamada; S Nakamura; H Yamamura
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

5.  Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Johannes Bloehdorn; Sebastian Hafner; Andreas Bühler; Till Seiler; Dirk Kienle; Dirk Winkler; Markus Bangerter; Richard F Schlenk; Axel Benner; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2006-01-17       Impact factor: 44.544

6.  A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).

Authors:  Antony C Bakke; Zoe Purtzer; Jose Leis; James Huang
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

7.  Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases.

Authors:  S Latour; L M Chow; A Veillette
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

8.  Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome.

Authors:  Sigi Kay; Yair Herishanu; Marjorie Pick; Ori Rogowski; Shoshana Baron; Elizabeth Naparstek; Aaron Polliack; Varda R Deutsch
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

9.  Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.

Authors:  Remi Letestu; Andy Rawstron; Paolo Ghia; Neus Villamor; Nancy Boeckx; Nancy Boeckx Leuven; Sebastian Boettcher; Anne Mette Buhl; Jan Duerig; Rachel Ibbotson; Alexander Kroeber; Anton Langerak; Magali Le Garff-Tavernier; Ian Mockridge; Alison Morilla; Ruth Padmore; Laura Rassenti; Matthias Ritgen; Medhat Shehata; Piotr Smolewski; Peter Staib; Michel Ticchioni; Clare Walker; Florence Ajchenbaum-Cymbalista
Journal:  Cytometry B Clin Cytom       Date:  2006-07-15       Impact factor: 3.058

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  4 in total

1.  Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.

Authors:  Yin-Hua Wang; Zhi-Jian Zou; Ling Liu; Li-Na Zhang; Cheng Fang; Dan-Xia Zhu; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

2.  Chronic lymphocytic leukemia involving the breast parenchyma, mimicker of invasive breast cancer: differentiation on breast MRI.

Authors:  Vandana Dialani; Kalpana Mani; Nicole B Johnson
Journal:  Case Rep Med       Date:  2013-09-18

3.  High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

Authors:  José A García-Marco; Javier López Jiménez; Valle Recasens; Miguel Fernández Zarzoso; Eva González-Barca; Nieves Somolinos De Marcos; M Jose Ramírez; Francisco Javier Peñalver Parraga; Lucrecia Yañez; Javier De La Serna Torroba; Maria Dolores Garcia Malo; Guillermo Deben Ariznavarreta; Ernesto Perez Persona; M Angeles Ruiz Guinaldo; Raquel De Paz Arias; Elena Bañas Llanos; Isidro Jarque; M Del Carmen Fernandez Valle; Ana Carral Tatay; Jaime Perez De Oteyza; Eva Maria Donato Martin; Inmaculada Perez Fernández; Rafael Martinez Martinez; M Angeles Andreu Costa; Diana Champ; Julio García Suarez; Marcos González Díaz; Secundino Ferrer; Félix Carbonell; José A García-Vela
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

Review 4.  Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review.

Authors:  Paulina Stefaniuk; Julia Onyszczuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2021-02-12       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.